Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
West China Hospital
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Pfizer
Seagen Inc.
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
Fondazione Policlinico Universitario Agostino Gemelli IRCCS